LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination

Garibashvili, Tamara; Heckmann, Josef G.

doi:10.1186/s42466-022-00187-8

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst the 3 perceived episodes of palpitations captured on ECG showed sinus rhythm, autonomic dysfunction has been well documented in anti-LGI-1 AE. 5,6,11 Indeed, Lewis et al 5 have described a case of anti-LGI-1 AE following the mRNA Pfizer vaccine that presented with sporadic heart palpitations, whilst cognition was affected months later. Further to this, Garibashvili and Heckmann 6 detailed cardiac pauses as a presenting complaint several days before the onset of FBDS following administration of the viral vector ChAdOx1 vaccine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-LGI-1 Limbic Encephalitis and Autoimmune Epilepsy Following a Third Dose of COVID-19 Vaccination: A Case Report

Mullan,

Kinney

2024

The Neurohospitalist

View full text Add to dashboard Cite

Anti-leucine rich glioma inactivated 1 (LGI-1) autoimmune encephalitis (AE) typically presents with cognitive impairment, faciobrachial dystonic seizures (FBDS) and hyponatraemia. Reports are growing of neurological complications following coronavirus disease 2019 (COVID-19) vaccination. Here we describe a 50 year old man who developed anti-LGI-1 limbic encephalitis and autoimmune epilepsy 4 days following a dose of the mRNA Pfizer COVID-19 vaccine (of note, his first two vaccinations were viral vector ChAdOX1-S). He presented with focal aware seizures characterised by short-lived episodes of confusion, emotional distress and déjà vu associated with palpitations. He also reported subacute progressive amnesia. He responded well to high-dose steroid and subsequent immunoglobulin therapy. To our knowledge, this is the first reported case of anti-LGI-1 AE following a mixed COVID-19 vaccination regimen. We aim to complement the early literature on this post-COVID-19 vaccination phenomenon.

show abstract

Section: Discussionmentioning

confidence: 99%

“…2 Cases of anti-LGI-1 AE have now been described following immunisation with the COVID-19 mRNA (BNT162b2/Pfizer & CX-024414/Moderna) and viral vector (ChAdOx1-S/Astra-Zeneca & Ad26.COV2.S/Johnson & Johnson) vaccines. 3-7 Here we describe a 50 year old man who developed anti-LGI-1 AE following a mixed vaccination regimen.…”

Section: Introductionmentioning

confidence: 98%